Piper Jaffray Downgrades Sequenom Stock | GenomeWeb

NEW YORK (GenomeWeb News) – Piper Jaffray today downgraded shares of Sequenom to Neutral, saying that its fight to stay ahead of competitors in the non-invasive fetal chromosome abnormalities testing space may result in greater costs to the company, while its ability to get reimbursement remains uncertain.

The investment bank previously had an Overweight rating on the San Diego-based firm. Piper Jaffray also lowered the price target on Sequenom's shares to $5 from $6.50.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.